Zhuhai Sailong Pharmaceutical Co Ltd (002898) fair value: what the stock is really worth
As of Jul 16, 2026: fair value of Zhuhai Sailong Pharmaceutical Co Ltd ¥0.52, price ¥0.37, upside +41.3%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Zhuhai Sailong Pharmaceutical Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ¥0.3200 – ¥18.58 · fair‑value band ¥0.3815 – ¥0.6618 · the ¥0.3700 price screens below the ¥0.5227 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Zhuhai Sailong Pharmaceutical Co in your weekly email
Every Wednesday you see whether Zhuhai Sailong Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China.
Show more
Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pantoprazole sodium products, etc. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding drugs, analgesics, and other fields. Sailong Pharmaceutical Group Co.,Ltd. was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd. and changed its name to Sailong Pharmaceutical Group Co.,Ltd. in September 2021. The company was founded in 2002 and is based in Zhuhai, China.
Stock analysis
Zhuhai Sailong Pharmaceutical Co Ltd (002898) currently trades at ¥0.3700, while our model-based Fair Value estimate is ¥0.5227, implying the stock looks roughly 29.2% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 94/100, which puts the evidence level at low.
Scenario range: ¥0.3815 (bear) to ¥0.6618 (bull), the price of ¥0.3700 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Zhuhai Sailong Pharmaceutical Co Ltd reported revenue of 519M CNY in FY2025 versus 247M CNY in FY2021, a compound +20.4%/yr. Reported net income was −121M CNY in FY2025.
Key figures
Market cap 65.1M CNY (≈ $9.7M) · P/S ratio 0.11 · EPS (TTM) ¥−0.7300 · Dividend yield 9.7% · Net margin −23.4% · Return on equity −29.1% · Return on assets (EBIT) −1.8% · Operating margin −1.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 41%, 002898 screens cheaper than that median.
Fair Value models
Bear ¥0.3815Fair Value ¥0.5227Bull ¥0.6618
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+96.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.9%
Start year 2020 (pandemic). Over 10 years: +8.1% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−38.9% (2020) → −4.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Zhuhai Sailong Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 6/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score41 · Below median
Fair Value upside+41.3% · Top 25%
Profitability
Return on assets−3.4% · Above median
Net margin (TTM)−20.9% · Below median
Operating margin (TTM)−1.2% · Below median
Growth and dividend
Revenue growth183.8% · Top 25%
Dividend yield (TTM)9.7% · Top 25%
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Zhuhai Sailong Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/002898
Frequently asked questions
Is Zhuhai Sailong Pharmaceutical Co Ltd (002898) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥0.5227 versus the last price from Jul 16, 2026 of ¥0.3700, about +41% upside (undervalued).
What is the fair value of 002898?
Our model-based fair value for Zhuhai Sailong Pharmaceutical Co Ltd is ¥0.5227 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Jul 16, 2026): ¥0.3700.
What is the quality score of 002898?
Zhuhai Sailong Pharmaceutical Co Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhuhai Sailong Pharmaceutical Co Ltd (002898)?
Our model-based price target is the fair value of ¥0.5227 (as of Sep 24, 2026) from 2 valuation models. Cautious scenario ¥0.3815, optimistic scenario ¥0.6618. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhuhai Sailong Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at ¥0.5227, about +41% upside versus the last price from Jul 16, 2026 of ¥0.3700 (undervalued). Cautious scenario ¥0.3815, optimistic scenario ¥0.6618. The calculation is refreshed regularly with new filings.
What is the revenue of Zhuhai Sailong Pharmaceutical Co Ltd (002898)?
Zhuhai Sailong Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 618M CNY (latest available figure, as of Sep 24, 2026).
Does Zhuhai Sailong Pharmaceutical Co Ltd pay a dividend?
Zhuhai Sailong Pharmaceutical Co Ltd currently shows a dividend yield of about 9.68% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Zhuhai Sailong Pharmaceutical Co Ltd (002898)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhuhai Sailong Pharmaceutical Co Ltd it is ¥0.5227 per share (as of Sep 24, 2026), against a price of ¥0.3700. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Zhuhai Sailong Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 002898 trades below its calculated fair value: price ¥0.3700, fair value ¥0.5227, a gap of about +41% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002898?
No. The price is what the market pays today (¥0.3700); the fair value is what the company's own numbers justify (¥0.5227). For Zhuhai Sailong Pharmaceutical Co Ltd the two are ¥0.1527 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhuhai Sailong Pharmaceutical Co Ltd worth?
The market values Zhuhai Sailong Pharmaceutical Co Ltd at about 65.1M CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥0.3700; our models calculate a fair value of ¥0.5227 per share.
What do the bullish and bearish scenarios say about 002898?
Our models span a range for Zhuhai Sailong Pharmaceutical Co Ltd: cautious scenario ¥0.3815, base ¥0.5227, optimistic ¥0.6618 per share (as of Sep 24, 2026, price ¥0.3700). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Zhuhai Sailong Pharmaceutical Co Ltd (002898)?
Balance-sheet figures for Zhuhai Sailong Pharmaceutical Co Ltd (as of Sep 24, 2026): return on equity −29.1%, debt of 0.02 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
Which stocks are comparable to Zhuhai Sailong Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhuhai Sailong Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price ¥0.3700, calculated fair value ¥0.5227 (+41%), Quality Score 43/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002898 calculated?
We run Zhuhai Sailong Pharmaceutical Co Ltd through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥0.5227, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Zhuhai Sailong Pharmaceutical Co Ltd currently trades 29 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhuhai Sailong Pharmaceutical Co Ltd (002898)?
The latest price we hold is from Jul 16, 2026 and stands at ¥0.3700. Our model-based fair value is ¥0.5227, about +41% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhuhai Sailong Pharmaceutical Co Ltd right now?
The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (¥0.3815). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Zhuhai Sailong Pharmaceutical Co Ltd
How large is the market capitalisation of Zhuhai Sailong Pharmaceutical Co Ltd (002898)?
The market capitalisation of Zhuhai Sailong Pharmaceutical Co Ltd is 65.1M CNY (≈ $9.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhuhai Sailong Pharmaceutical Co Ltd (002898)?
The price-to-sales ratio of Zhuhai Sailong Pharmaceutical Co Ltd is 0.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhuhai Sailong Pharmaceutical Co Ltd (002898)?
Earnings per share at Zhuhai Sailong Pharmaceutical Co Ltd are ¥−0.7300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zhuhai Sailong Pharmaceutical Co Ltd (002898)?
The dividend yield of Zhuhai Sailong Pharmaceutical Co Ltd is 9.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zhuhai Sailong Pharmaceutical Co Ltd (002898)?
The net margin of Zhuhai Sailong Pharmaceutical Co Ltd is −23.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhuhai Sailong Pharmaceutical Co Ltd (002898)?
The return on equity (ROE) of Zhuhai Sailong Pharmaceutical Co Ltd is −29.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhuhai Sailong Pharmaceutical Co Ltd (002898)?
On an EBIT basis the return on assets of Zhuhai Sailong Pharmaceutical Co Ltd is −1.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhuhai Sailong Pharmaceutical Co Ltd (002898)?
The operating margin of Zhuhai Sailong Pharmaceutical Co Ltd is −1.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhuhai Sailong Pharmaceutical Co Ltd (002898)?
Revenue at Zhuhai Sailong Pharmaceutical Co Ltd is growing +184% versus a year earlier (3y avg +25.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zhuhai Sailong Pharmaceutical Co Ltd (002898)?
Earnings per share at Zhuhai Sailong Pharmaceutical Co Ltd are growing −49.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zhuhai Sailong Pharmaceutical Co Ltd (002898) generate?
The free cash flow of Zhuhai Sailong Pharmaceutical Co Ltd is −4.3M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Zhuhai Sailong Pharmaceutical Co Ltd (002898) carry?
The net debt of Zhuhai Sailong Pharmaceutical Co Ltd is 31.9M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Zhuhai Sailong Pharmaceutical Co Ltd in the live analysis
One click puts Zhuhai Sailong Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
